Preferences for Adjuvant Immunotherapy in Resected Stage III Melanoma
September 12 @ 6:00 pm - 8:00 pm EDT
Presenter: Ann Livingstone, University of Sydney
Ann was recently awarded her PhD. She has a keen interest in patient preferences in trial-based and modelled economic evaluation. In addition, she works as an evaluator for the Australian Medical Services Advisory Committee, reviewing and critiquing evidence to inform government policy decision-making regarding health technologies.
Adjuvant immunotherapy has revolutionised the management of resectable melanoma, substantially reducing the chance of recurrence but at the risk of immune-related adverse events (AE). However, the choice of adjuvant (additional) treatments can be contentious.
A discrete choice experiment (DCE) included respondents with resected stage III melanoma considering or having received adjuvant immunotherapy. Respondents chose between twelve randomly presented choice tasks of two alternative options (adjuvant immunotherapy versus observation without adjuvant immunotherapy). The two options varied across two-three levels of six attributes: chance of 3-year melanoma recurrence, mild, permanent, or fatal AE, drug regimen, and out-of-pocket costs.
This presentation will discuss the results of respondents’ preferences for adjuvant immunotherapy as a treatment for stage III resected melanoma.